17 hours HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal Zacks
Hoth stock soars as a mid-stage study meets the goal, showing significant improvement in skin toxicities related to EFGR inhibitor therapy in all HT-001-treated patients.
X